Literature DB >> 31911451

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis.

Yaqing Zhang1,2, Jenny Lazarus3, Nina G Steele4, Wei Yan3, Ho-Joon Lee5, Zeribe C Nwosu5, Christopher J Halbrook5, Rosa E Menjivar6, Samantha B Kemp7, Veerin R Sirihorachai8, Ashley Velez-Delgado4, Katelyn Donahue8, Eileen S Carpenter9, Kristee L Brown3, Valerie Irizarry-Negron3, Anna C Nevison3, Alekya Vinta10, Michelle A Anderson9, Howard C Crawford2,5,9, Costas A Lyssiotis2,5,9, Timothy L Frankel3, Filip Bednar1, Marina Pasca di Magliano1,2,4,6.   

Abstract

Regulatory T cells (Treg) are abundant in human and mouse pancreatic cancer. To understand the contribution to the immunosuppressive microenvironment, we depleted Tregs in a mouse model of pancreatic cancer. Contrary to our expectations, Treg depletion failed to relieve immunosuppression and led to accelerated tumor progression. We show that Tregs are a key source of TGFβ ligands and, accordingly, their depletion reprogramed the fibroblast population, with loss of tumor-restraining, smooth muscle actin-expressing fibroblasts. Conversely, we observed an increase in chemokines Ccl3, Ccl6, and Ccl8 leading to increased myeloid cell recruitment, restoration of immune suppression, and promotion of carcinogenesis, an effect that was inhibited by blockade of the common CCL3/6/8 receptor CCR1. Further, Treg depletion unleashed pathologic CD4+ T-cell responses. Our data point to new mechanisms regulating fibroblast differentiation in pancreatic cancer and support the notion that fibroblasts are a heterogeneous population with different and opposing functions in pancreatic carcinogenesis. SIGNIFICANCE: Here, we describe an unexpected cross-talk between Tregs and fibroblasts in pancreatic cancer. Treg depletion resulted in differentiation of inflammatory fibroblast subsets, in turn driving infiltration of myeloid cells through CCR1, thus uncovering a potentially new therapeutic approach to relieve immunosuppression in pancreatic cancer.See related commentary by Aykut et al., p. 345.This article is highlighted in the In This Issue feature, p. 327. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31911451      PMCID: PMC7224338          DOI: 10.1158/2159-8290.CD-19-0958

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  71 in total

1.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.

Authors:  Mitsuro Kanda; Hanno Matthaei; Jian Wu; Seung-Mo Hong; Jun Yu; Michael Borges; Ralph H Hruban; Anirban Maitra; Kenneth Kinzler; Bert Vogelstein; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-05       Impact factor: 22.682

2.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.

Authors:  Heidi Griesmann; Christof Drexel; Nada Milosevic; Bence Sipos; Jonas Rosendahl; Thomas M Gress; Patrick Michl
Journal:  Gut       Date:  2016-03-24       Impact factor: 23.059

4.  CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Authors:  Daniel J Dairaghi; Babatunde O Oyajobi; Anjana Gupta; Brandon McCluskey; Shichang Miao; Jay P Powers; Lisa C Seitz; Yu Wang; Yibin Zeng; Penglie Zhang; Thomas J Schall; Juan C Jaen
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

5.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Authors:  Rafael Winograd; Katelyn T Byrne; Rebecca A Evans; Pamela M Odorizzi; Anders R L Meyer; David L Bajor; Cynthia Clendenin; Ben Z Stanger; Emma E Furth; E John Wherry; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2015-02-12       Impact factor: 11.151

6.  Canonical wnt signaling is required for pancreatic carcinogenesis.

Authors:  Yaqing Zhang; John P Morris; Wei Yan; Heather K Schofield; Austin Gurney; Diane M Simeone; Sarah E Millar; Timothy Hoey; Matthias Hebrok; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-06-12       Impact factor: 12.701

7.  Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.

Authors:  John P Morris; David A Cano; Shigeki Sekine; Sam C Wang; Matthias Hebrok
Journal:  J Clin Invest       Date:  2010-01-11       Impact factor: 14.808

8.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

9.  MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.

Authors:  Atsuo Ochi; Andrew H Nguyen; Andrea S Bedrosian; Harry M Mushlin; Saman Zarbakhsh; Rocky Barilla; Constantinos P Zambirinis; Nina C Fallon; Adeel Rehman; Yuliya Pylayeva-Gupta; Sana Badar; Cristina H Hajdu; Alan B Frey; Dafna Bar-Sagi; George Miller
Journal:  J Exp Med       Date:  2012-08-20       Impact factor: 14.307

Review 10.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Haoqiang Ying; Prasenjit Dey; Wantong Yao; Alec C Kimmelman; Giulio F Draetta; Anirban Maitra; Ronald A DePinho
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361

View more
  86 in total

Review 1.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

2.  The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis.

Authors:  Lawrence N Barrera; P Matthew Ridley; Camino Bermejo-Rodriguez; Eithne Costello; Pedro A Perez-Mancera
Journal:  J Physiol Biochem       Date:  2022-06-29       Impact factor: 4.158

Review 3.  Regulation and modulation of antitumor immunity in pancreatic cancer.

Authors:  Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-08-17       Impact factor: 25.606

4.  Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer.

Authors:  Vineet K Gupta; Nikita S Sharma; Brittany Durden; Vanessa T Garrido; Kousik Kesh; Dujon Edwards; Dezhen Wang; Ciara Myer; Beatriz Mateo-Victoriano; Sai Sundeep Kollala; Yuguang Ban; Zhen Gao; Sanjoy K Bhattacharya; Ashok Saluja; Pankaj K Singh; Sulagna Banerjee
Journal:  Cancer Res       Date:  2021-05-14       Impact factor: 12.701

5.  Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.

Authors:  Ivana Peran; Sivanesan Dakshanamurthy; Matthew D McCoy; Anastasia Mavropoulos; Bedilu Allo; Aimy Sebastian; Nicholas R Hum; Sara C Sprague; Kelly A Martin; Michael J Pishvaian; Eveline E Vietsch; Anton Wellstein; Michael B Atkins; Louis M Weiner; Andrew A Quong; Gabriela G Loots; Stephen S Yoo; Shahin Assefnia; Stephen W Byers
Journal:  Gastroenterology       Date:  2020-12-09       Impact factor: 22.682

6.  Disease-induced immunomodulation at biomaterial scaffolds detects early pancreatic cancer in a spontaneous model.

Authors:  Grace G Bushnell; Sophia M Orbach; Jeffrey A Ma; Howard C Crawford; Max S Wicha; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Biomaterials       Date:  2020-12-23       Impact factor: 12.479

7.  Canonical Secretomes, Innate Immune Caspase-1-, 4/11-Gasdermin D Non-Canonical Secretomes and Exosomes May Contribute to Maintain Treg-Ness for Treg Immunosuppression, Tissue Repair and Modulate Anti-Tumor Immunity via ROS Pathways.

Authors:  Dong Ni; TingTing Tang; Yifan Lu; Keman Xu; Ying Shao; Fatma Saaoud; Jason Saredy; Lu Liu; Charles Drummer; Yu Sun; Wenhui Hu; Jahaira Lopez-Pastrana; Jin J Luo; Xiaohua Jiang; Eric T Choi; Hong Wang; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

Review 8.  Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Authors:  Yin Qianmei; Su Zehong; Wang Guang; Li Hui; Gaojian Lian
Journal:  Immunol Res       Date:  2021-07-24       Impact factor: 2.829

9.  Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer.

Authors:  Nina G Steele; Eileen S Carpenter; Samantha B Kemp; Veerin R Sirihorachai; Stephanie The; Lawrence Delrosario; Jenny Lazarus; El-Ad David Amir; Valerie Gunchick; Carlos Espinoza; Samantha Bell; Lindsey Harris; Fatima Lima; Valerie Irizarry-Negron; Daniel Paglia; Justin Macchia; Angel Ka Yan Chu; Heather Schofield; Erik-Jan Wamsteker; Richard Kwon; Allison Schulman; Anoop Prabhu; Ryan Law; Arjun Sondhi; Jessica Yu; Arpan Patel; Katelyn Donahue; Hari Nathan; Clifford Cho; Michelle A Anderson; Vaibhav Sahai; Costas A Lyssiotis; Weiping Zou; Benjamin L Allen; Arvind Rao; Howard C Crawford; Filip Bednar; Timothy L Frankel; Marina Pasca di Magliano
Journal:  Nat Cancer       Date:  2020-10-26

10.  WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.

Authors:  Mei-Hua Jin; Ah-Rong Nam; Ju-Hee Bang; Kyoung-Seok Oh; Hye-Rim Seo; Jae-Min Kim; Jeesun Yoon; Tae-Yong Kim; Do-Youn Oh
Journal:  Gastric Cancer       Date:  2021-03-16       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.